Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions
- 1Department of Psychiatry Dalhousie University Halifax Nova Scotia Canada
- 2Nova Scotia Health Halifax Nova Scotia Canada
- 3School of Psychology University of Ottawa Ottawa Ontario Canada
Abstract
Objective: Eating disorders (EDs) are characterized by high rates of psychiatric comorbidity and suboptimal treatment outcomes. There remain critical gaps in research, including the exploration of effective transdiagnostic interventions. This forum article examines the potential of psilocybin treatment (PT) as a transdiagnostic intervention for EDs and common comorbidities, including the implications for alternative nosological frameworks, trial design, and clinical care.
Method: A narrative review was conducted synthesizing clinical, mechanistic, and conceptual literature on PT for EDs and common psychiatric comorbidities. Searches of academic databases were supplemented by hand‐searching and clinical trial registries. Thematic synthesis focused on transdiagnostic clinical evidence, mechanistic theories, and implications for the Hierarchical Taxonomy of Psychopathology (HiTOP), Research Domain Criteria (RDoC), treatment development, and clinical trial design.
Results: Preliminary clinical evidence supports the feasibility, safety, and therapeutic effects of PT for EDs, with robust transdiagnostic effects observed across comorbid conditions. Proposed mechanisms (i.e., serotonergic receptor agonism, psychoplastogenic effects, neural network desynchronization) target shared vulnerabilities that map onto dimensional constructs in HiTOP (Emotional Dysfunction superspectrum, Internalizing spectrum) and RDoC (negative/positive valence, cognitive, and social process domains) nosologies. Future research should explore pragmatic trial designs and dimensional outcome measures to capture the real‐world complexities of PT for EDs.
Discussion: PT demonstrates transdiagnostic therapeutic potential for EDs, and the advancement of dimensional nosologies, complex intervention frameworks, and personalized treatment protocols may address existing gaps in research and clinical care.
Related
- Call for a transdiagnostic and ecologically valid assessment of youth psychopathology in daily life
- Latent transdiagnostic dimensions linking sleep and psychopathology map onto distinct connectome-wide networks
- Artificial Intelligence-Guided Extracellular Vesicle Platforms for Diagnosis and Treatment of Chronic Kidney Disease: A Scoping Review and Future Directions
- Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
- Treatment Strategies and Future Directions for Locally Advanced Pancreatic Cancer
BibTeX
@article{koning2026psilocybin,
title = {{Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions}},
author = {Elena Koning and Jérémie Richard and Aaron Keshen},
journal = {The International Journal of Eating Disorders},
year = {2026},
month = jul,
doi = {10.1002/eat.70164},
url = {https://doi.org/10.1002/eat.70164},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions
AU - Elena Koning
AU - Jérémie Richard
AU - Aaron Keshen
PY - 2026
DA - 2026/07/02
JO - The International Journal of Eating Disorders
DO - 10.1002/eat.70164
UR - https://doi.org/10.1002/eat.70164
AB - Objective: Eating disorders (EDs) are characterized by high rates of psychiatric comorbidity and suboptimal treatment outcomes. There remain critical gaps in research, including the exploration of effective transdiagnostic interventions. This forum article examines the potential of psilocybin treatment (PT) as a transdiagnostic intervention for EDs and common comorbidities, including the implications for alternative nosological frameworks, trial design, and clinical care. Method: A narrative review was conducted synthesizing clinical, mechanistic, and conceptual literature on PT for EDs and common psychiatric comorbidities. Searches of academic databases were supplemented by hand‐searching and clinical trial registries. Thematic synthesis focused on transdiagnostic clinical evidence, mechanistic theories, and implications for the Hierarchical Taxonomy of Psychopathology (HiTOP), Research Domain Criteria (RDoC), treatment development, and clinical trial design. Results: Preliminary clinical evidence supports the feasibility, safety, and therapeutic effects of PT for EDs, with robust transdiagnostic effects observed across comorbid conditions. Proposed mechanisms (i.e., serotonergic receptor agonism, psychoplastogenic effects, neural network desynchronization) target shared vulnerabilities that map onto dimensional constructs in HiTOP (Emotional Dysfunction superspectrum, Internalizing spectrum) and RDoC (negative/positive valence, cognitive, and social process domains) nosologies. Future research should explore pragmatic trial designs and dimensional outcome measures to capture the real‐world complexities of PT for EDs. Discussion: PT demonstrates transdiagnostic therapeutic potential for EDs, and the advancement of dimensional nosologies, complex intervention frameworks, and personalized treatment protocols may address existing gaps in research and clinical care.
SN - 0276-3478
SN - 1098-108X
ER -